Compagnie Lombard Odier S Cm A Cure Vac N.V. Transaction History

Compagnie Lombard Odier S Cm A

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 18, 2024	SELL	$2.31 - $4.99 $8,847 - $19,111	-3,830 Reduced 56.08%	3,000 $10,000
Q1 2022 Apr 27, 2022	BUY	$14.73 - $35.25 $44,190 - $105,750	3,000 Added 78.33%	6,830 $134,000
Q4 2021 Feb 09, 2022	BUY	$33.72 - $48.22 $67,440 - $96,440	2,000 Added 109.29%	3,830 $131,000
Q3 2021 Oct 28, 2021	BUY	$49.26 - $74.5 $40,885 - $61,835	830 Added 83.0%	1,830 $100,000
Q2 2021 Jul 15, 2021	SELL	$56.91 - $127.53 $83,942 - $188,106	-1,475 Reduced 59.6%	1,000 $73,000
Q1 2021 Apr 23, 2021	BUY	$79.79 - $126.29 $197,480 - $312,567	2,475 New	2,475 $226,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.